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1. Introduction 
Diabetic macular edema represents one of the most important causes of visual morbidity in 
diabetes mellitus. The National Diabetes Information Clearinghouse estimates the 
prevalence of diabetes mellitus types 1 and 2 at 11.3% of the population above the age of 20, 
with an annual incidence of 1.9 million cases in the United States alone. In this population, 
the prevalence of diabetic macular edema is estimated at 30% of patients inflicted by the 
disease for 20 years or more. Diabetes mellitus is the leading cause of preventable blindness 
owing to both diabetic macular edema and complications of proliferative diabetic 
retinopathy (NDIC 2011). Thus once can expect that diabetic macular edema is a common 
entity in any Retina specialty practice with serious implications for vision loss if not treated 
in a timely and appropriate manner. Based on the critical findings of the Early Treatment in 
Diabetic Retinopathy Study, the standard of care has been focal laser photocoagulation 
therapy along with strong recommendations for strict blood glucose and blood pressure 
control. However since then, the spectrum of therapies for diabetic macular edema has 
expanded and continues to evolve. The use of steroid therapy and anti-vascular endothelial 
growth factor biologics have been compared to focal laser photocoagulation in order to 
establish more treatment options with equivalent efficacy and safety. 
The following chapter is a comprehensive review of the basic pathophysiology, 
symptomatology, clinical findings, diagnostic methods, indications for intervention, and 
treatment modalities of diabetic macular edema. Careful attention is given to the review of 
treatment modalities, including steroid therapy, Anti-VEGF pharmacotherapy (sister drugs 
Lucentis (ranibizumab) and Avastin (bevacizumab)) and surgical techniques. A literature 
review is also summarized comparing these methods to focal laser photocoagulation 
therapy. Thus this chapter is designed to give the reader a fuller understanding of the 
diabetic macular edema as a clinical entity and how it can be addressed so as to preserve 
vision. 
2. Pathophysiology 
Diabetic macular edema is a microvascular complication of diabetes mellitus with serious 
implications for vision loss. The central pathophysiologic event is retinal capillary 
incompetence and leakage. Several biochemical hypotheses exist to explain the damage to 
retinal capillary constituents in diabetes mellitus. Prolonged hyperglycemia has been 
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implicated in direct injury to retinal capillary endothelial cell and pericytes and to a decline 
in cell division (Engerman 1987). Cells in the body produce energy from the metabolism of 
glucose. The sorbitol (or polyol) pathway concurrently employs aldose reductase to reduce 
unused glucose to sorbitol (Brownlee 2001). Under normal circumstances cells metabolize 
glucose primarily via glycolysis, particularly because at a physiologic serum concentration, 
aldose reductase has a low affinity for glucose. However, high serum glucose concentrations 
can saturate the glycolysis pathway, making excess glucose molecules available for 
reduction to sorbitol by the avidly-binding aldose reductase. Excessive activation of the 
sorbitol pathway in hyperglycemia results in an accumulation of sorbitol in the intracellular 
space which has been considered toxic to cells, in particular to retinal capillary endothelial 
cells and pericytes (Brownlee 2001).  
Retinal capillary walls normally consist of a succinct network of endothelial cells and mural 
pericytes, which exist in a deliberate one-to-one ratio. In the 1950s, Kuwabara and Cogan 
developed Trypsin digest studies in retinal tissue of diabetic human subjects, which made 
possible the close examination of the retinal vasculature by light microscopy (Kuwabara 
1960). These retinal digest studies were the first of their kind to demonstrate the key 
pathologic events of diabetic retinopathy. The biochemical derangements of diabetes 
mellitus cause a preferential loss of pericytes, identified histologically as empty “balloon-
like spaces” or “ghost cells” along retinal capillary walls (Kuwabara 1960). Immunologic 
studies have demonstrated that mural pericytes contain properties that make them 
structurally analogous to the smooth muscle layer of larger scale blood vessels. The 
contractile nature and tonus of pericytes contribute to the structural integrity of the retinal 
capillary wall (Herman 1985). Therefore, a loss of mural pericytes may cause focal 
weakening and saccular dilatation of retinal capillaries, identified biomicroscopically as 
microaneurysms. Microaneurysms are readily detected on close fundoscopic examination 
and by fluorescein angiography and are one of the earliest signs of nonproliferative diabetic 
retinopathy (Freidenwald 1950). They are visually indistinguishable from dot intraretinal 
hemorrhages and thus represent areas of focal retinal vasculature incompetence.  
The breakdown of the inner blood retinal barrier at the level of the retinal capillary 
endothelial cells likewise contributes to capillary incompetence. This breakdown largely 
occurs with an opening of tight junctions, or zonulae occludentes, between adjacent 
endothelial cells (Green 1985). The pathophysiologic outcome of inner blood retinal barrier 
compromise and abnormally permeable microaneurysms is an unchecked leakage of 
erythrocytes, plasma, and lipoproteins into the retinal interstitium. Retinal edema results 
once this fluid leakage overwhelms the capacity of the retinal pigment epithelial pump to 
remove it. The sequelae of vascular incompetence and retinal edema include (1) 
precipitation of serum lipoproteins in the retinal interstitium, causing a disruption of the 
delicate retinal architecture and (2) retinal arteriolar closure, resulting in focal retinal 
ischemia (Ryan 1989).  
Retinal arteriolar closure characterizes a more advanced stage of nonproliferative 
retinopathy and carries more serious implications for widespread retinal ischemia and 
progression to proliferative disease (Ryan 1989). Several mechanisms of arteriolar occlusion 
have been hypothesized, implicating both intraluminal and extraluminal forces. Firstly, 
erythrocyte and platelet agglutination and defective fibrinolysis may cause intraluminal 
occlusion of arterioles (Little 1981) Endothelial cell basement membrane thickening, a 
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general histologic characteristic of diabetes mellitus, potentially causes luminal narrowing 
and occlusion. The accumulation of interstitial fluid and protein leads to increased tissue 
oncotic pressure and tissue turgor which may cause vascular closure by means of direct 
compression (Ryan 1989). Macular ischemia resulting from closure of retinal capillaries and 
arterioles may exacerbate concurrent macular edema.  
Deformational macular edema caused by tractional membranes on the retinal surface is 
often observed in diabetic retinopathy either alone or in the presence of underlying diabetic 
macular edema (Clarkson 1977). Epiretinal membranes and a taut posterior hyaloid are the 
most common examples of tractional membranes. Epiretinal membranes are fibrocellular 
membranes caused by the migration and proliferation of retinal glial cells along the retinal 
surface. Their origin can be idiopathic or as a consequence of diabetic retinopathy or retinal 
vascular disorders. Depending on their severity, epiretinal membranes can cause retinal 
distortion and tractional retinal edema that is evident on both fundoscopy and fluorescein 
angiography (as cystoid macular edema). Epiretinal membranes can thus exacerbate 
underlying DME. The posterior hyaloid face of the vitreous can likewise cause 
deformational macular edema by exerting antero-posterior forces on the macula, as 
observed in the vitreomacular traction (VMT) syndrome. This is an idiopathic condition 
characterized by abnormal adhesion of the posterior hyaloid to the macula. As seen with 
epiretinal membranes, there may be tractional edema causing leakage in the macula and 
from the optic nerve head on fluorescein angiography (Hikichi 1995). Several hypotheses 
have attempted to explain the VMT syndrome: (1) Glycation of the vitreous: abnormal 
crosslinking of cortical vitreous in systemic hyperglycemic with tractional adherence to the 
macula causing a secondary deformation of retinal architecture (Dillinger 2004); (2) 
sequestration of pro-inflammatory factors or compounds in the pre-macular area by the 
posterior hyaloid that increase vascular permeability (Dillinger 2004); (3) frank, idiopathic 
contraction of the posterior hyaloid face with resultant deformational edema (Figueroa 
2008). 
The metabolic derangements of diabetes mellitus take a serious toll on the smallest 
constituents of the retinal vasculature. These early changes eventually manifest themselves 
on a macroscopic level, causing a generalized dysfunction of the blood retinal barrier, 
pathologic retinal edema, retinal vascular compromise and closure, tissue ischemia, and the 
potential for serious loss of visual acuity.  
3. Clinical considerations 
Macular edema is the terminology applied when careful fundoscopic examination reveals 
retinal thickening (with or without retinal exudates) within two disc diameters of the central 
macula. It may be observed at any stage of diabetic retinopathy, from minimal background 
diabetic retinopathy to active proliferative disease. The classic signs of background 
(nonproliferative) diabetic retinopathy are dot-blot hemorrhages, microaneurysms, hard 
exudates, and cotton wool spots. Dot-blot hemorrhages are intraretinal hemorrhages located 
in the outer retinal layers that directly result from incompetent retinal capillaries. Small, dot 
hemorrhages may be clinically indistinguishable from microaneurysms; whereas “blot” 
hemorrhages tend to be larger with indistinct borders located in the outer plexiform layer. 
Hard exudates are discrete, often confluent, yellow-white intraretinal accumulations of 
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precipitated serum lipid. Their presence is likewise strong evidence of retinal capillary 
leakage. Cotton wool spots are thusly named due to their fluffy, white appearance in the 
retina. They represent foci of ischemic retinal whitening in areas of retinal capillary closure. 
Cotton wool spots may resolve over time without necessarily promoting retinal 
neovascularization. However, a high density of cotton wool spots in any single area may 
suggest more severe underlying ischemia and a greater risk of progression to proliferative 
disease. 
Macular edema may exist in several forms, each of which require specific treatment 
strategies and may vary greatly in terms of visual prognosis. Macular edema is primarily 
characterized as focal or diffuse. Focal macular edema represents retinal thickening 
involving localized areas of the macula, usually from a single microaneurysm or of clusters 
of them. Focal edema is often in the form of a microaneurysm with a surrounding circinate 
ring of precipitated hard exudates (or plasma lipoproteins), which delineates edematous 
from non-edematous retina (Gass 1987). Plasma lipoproteins most commonly accumulate in 
the outer plexiform layer but may be deposited in the subretinal space causing an 
independent decline in vision if the fovea is involved. Diffuse macular edema corresponds 
to a more generalized retinal capillary incompetence with extensive fluid leakage in the 
macula. Additionally, although not generally considered an element of diabetic macular 
edema (DME), incompetence in the outer blood-retinal barrier has been implicated in 
diffuse edema (Bresnick 1986). Experimental animal models have suggested that loss of 
retinal pigment epithelial cell tight junctions and RPE necrosis in diabetes mellitus possibly 
lead to abnormal permeability from the choroid (Kirber 1980). This often leads to cystoid 
macular edema and is not necessarily associated with exudates. Both eyes are usually 
symmetrically affected, demonstrating the same severity of edema and visual acuity. 
Systemic factors such as glycemic control, blood pressure, and fluid retention status may 
alter the clinical appearance of diffuse macular edema, with periodic resolution and 
exacerbation even without therapeutic intervention (Ryan 1989). 
Recently, the use of the terminology “focal” versus “diffuse” diabetic macular edema has 
come under scrutiny. Some critics of this terminology have argued that it is not precise as 
there may be great overlap between these two entities in terms of visual morbidity, 
management options, and prognosis. More accurate descriptors should ideally include 
information regarding the following characteristics: location and extent of edema, central 
foveal involvement or sparing, and the extent and location of associated exudation 
(Browning 2008).  
Macular edema is a common cause of visual acuity loss, particularly in the context of poorly 
controlled blood glucose levels. However, vision can be preserved for months to years even 
with clinically significant diabetic macular edema. Thus the presence of excellent visual 
acuity does not contraindicate treatment of diabetic macular edema. In the majority of cases, 
macular edema does eventually lead to a decline in visual acuity, which is potentially 
reversible if the edema is successfully treated once the diagnosis is made. Chronic DME can 
cause a profound disruption of the retinal architecture. Cystoid maculopathy, characterized 
by retinal degeneration and atrophy in the macula, is typically resistant to even aggressive 
therapy and holds a poor visual prognosis. 
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A consequence of retinal capillary and arteriolar closure in diabetic retinopathy is the 
disruption of the fine capillary network surrounding the fovea (Hayreh 2008). The end stage 
of retinal vascular incompetence, capillary and arteriolar closure is macular ischemia, which 
results from compromised oxygen delivery in the macula (Hayreh 2008). Retinal edema and 
exudation in DME will increase the length of the pathway for diffusion of oxygen in to the 
vessel-devoid foveal avascular zone (Hayreh 2008). The inability to sustain the oxygen 
demands of this tissue will invariably have visual consequences, particularly once 
breakdown of the perifoveal capillary network is documented angiographically. Visual 
acuity is generally not affected until the diameter of the foveal avascular zone (usually 500 
microns) exceeds 1000 microns (Ryan 1989). However, once this occurs, irreversible loss of 
visual acuity can be expected. Macular ischemia will compound diabetic macular edema; 
thus, when coexistent, it is often difficult to determine which has a greater effect on visual 
acuity. Such eyes tend to have poorer general prognosis, with a blunted response to focal 
laser therapy.  
4. Clinical assessment 
The characteristics of diabetic macular edema are best assessed by a combination of slit lamp 
biomicroscopy, fundus photography, fluorescein angiography, and more recently optical 
coherence tomography (OCT). The basic pathophysiologic lesions discussed above may be 
readily apparent in the posterior pole on fundoscopic examination with contact or 
noncontact lenses. Macular edema is detected as a thickening in the retinal layers with 
stereoscopic, binocular viewing. Mild retinal edema may escape detection whereas frank 
macular edema is typically quite apparent, particularly with coexisting intraretinal 
hemorrhage and hard exudate. Stereoscopic fundus photographs have been the standard 
method of quantifying diabetic macular edema in clinical trials (Davis 2008). 
In ophthalmoscopically normal eyes, early changes in diabetic retinopathy may be detected 
by fluorescein angiography. A fluorescein angiogram is obtained when information about 
the structure and integrity of the retinal circulation is needed. However, it should not be 
used specifically to evaluate for the presence of DME. Fluorescein dye (a green vegetable-
based dye) is injected into a vein in the antecubital fossa and a series of timed photographs 
are taken of the fundi. As previously stated, diabetic macular edema is a disease of retinal 
capillary incompetence with leakage of serum and blood products into the retinal 
interstitium. While fluorescein is largely bound to protein and the surface of erythrocytes in 
the blood column, approximately 20% of molecules are unbound (Richard 2008). Therefore, 
in the setting of inner blood retinal barrier compromise, there will be an egress of fluorescein 
into the retinal interstitium. The earliest evidence of this in background diabetic retinopathy 
is leakage from retinal microaneurysms, detectable as early punctate hyperfluorescence in 
the posterior pole. Macular edema is demonstrated as expanding hyperfluorescence from 
punctate foci in mid and late phases of the study. When cystoid macular edema is present, 
the leakage may be in a petaloid pattern. 
Time domain and spectral domain optical coherence tomography (OCT) are newer imaging 
modalities commonly employed in the evaluation of diabetic macular edema. OCT provides 
qualitative cross-sectional images and retinal thickness maps as well as quantitative 
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thickness estimates of the central macular subfield. The use of OCT as a diagnostic tool in 
diabetic macular edema has been investigated. Officially, the diagnosis of diabetic macular 
edema is made by specific fundoscopic criteria established by the ETDRS. Recent studies 
have compared OCT to fundus photography in order to validate the role of the former in 
diagnosing DME. For example, a 2008 study by the Diabetic Retinopathy Clinical 
Research Network demonstrated a moderate correlation between retinal thickness 
measurements rendered by time domain OCT (Zeiss Stratus OCT3) and area of retinal 
thickening determined by stereoscopic fundus photographs (Davis 2008). Furthermore, 
the authors report that OCT may be more sensitive than fundus photographs in 
measuring the change in retinal thickness over time and, in particular, after treatment of 
DME. While visual acuity itself remains the most important correlate of the severity of 
diabetic macular edema, this study demonstrated only a weak correlation between OCT 
retinal thickness estimates and visual acuity. Nevertheless, the group concluded that OCT 
is an acceptable method of quantifying diabetic macular edema and suggested the 
possibility of its use in future clinical trials evaluating the efficacy of treatment modalities. 
Furthermore, the use of OCT to guide focal laser photocoagulation therapy was suggested 
in a prospective interventional comparative study comparing it with fluorescein 
angiogram-guided treatment (Gallego-Pinazo 2011). 
OCT has become an indispensible imaging study in the early detection of diabetic macular 
edema and in the assessment of treatment response. OCT is likewise helpful in the diagnosis 
of tractional forces impacting macula edema such as epiretinal membranes and 
vitreomacular abnormalities, which are not as easily assessed by fundoscopy. Prior to such 
imaging techniques assessment of vitreomacular traction was certainly less accurate. 
5. Management 
The Early Treatment in Diabetic Retinopathy Study (ETDRS), sponsored by the National Eye 
Institute in 1979, was a benchmark in the management of diabetic macular edema (ETDRS 
1985). The ETDRS was a large-scale, multicenter, randomized clinical trial designed to 
investigate whether early treatment of macular edema by focal argon laser photocoagulation 
could prevent moderate visual loss, defined as a loss of three lines of vision or a doubling of 
the visual angle. Eyes with macular edema in the setting of mild to moderate 
nonproliferative diabetic retinopathy with a visual acuity of 20/40 or worse were recruited 
and divided into two treatment groups: immediate versus delayed focal laser 
photocoagulation. The standard technique and parameters of focal laser therapy were 
detailed by the ETDRS as follows: a laser spot size of 50-100 microns and duration of 0.10 
seconds to focal microaneurysms observed with contact lens fundoscopy. When the macular 
edema is more diffuse, a grid pattern of similar parameters may be applied. Laser burns are 
titrated to a slight graying of the treated retina (ETDRS 1985; ETDRS 1987). Based on three 
years of follow-up data, the ETDRS concluded that immediate focal photocoagulation 
halved the rate of moderate visual loss. When patients were stratified in terms of severity of 
initial macular edema, the benefit of immediate focal laser therapy was maximized in 
patients with “clinically significant macular edema” (CSME). As such, the ETDRS defined 
CSME, which is characterized as follows:  
www.intechopen.com
 
Diabetic Macular Edema 
 
199 
• retinal edema located at or within 500 microns of the foveal center 
• hard exudates at or within 500 microns of the foveal center if associated with thickening 
of adjacent retina  
• a zone of retinal thickening larger than 1 disc area within 1 disc diameter of the foveal 
center (ETDRS 1985) 
This treatment strategy implies that  is that macular edema which does not satisfy the above 
characteristics may be closely observed clinically until the criteria are satisfied (ETDRS 1987).  
Subclinical macular edema (SCME) is a term used to describe macular edema in which fluid 
or leakage is detected on optical coherence tomography or fluorescein angiography, but not 
detected clinically on examination, or if detected on examination, did not meet the definition 
of CSME as defined by the ETDRS. This has been quantified as a central retinal subfield 
thickness ranging from 200 to 300 microns (by third generation Zeiss Stratus OCT). A recent 
retrospective case-controlled study compared type II diabetics with SCME to age, sex, and 
disease duration-matched controls without macular edema (defined as central subfield 
thickness <200 microns). This study aimed to identify the risk factors and relative risk for 
progression to CSME from SCME. It found that a prior history of CSME, advancing age and 
graded increases in central retinal thickness over time increased the likelihood of 
progression to CSME in patients with sublinical edema (Bhavsar 2011).  
Further analysis of ETDRS data revealed that eyes with center-involving CSME (i.e. 
intraretinal fluid involving the fovea) versus eyes with CSME without central involvement 
(i.e. encroaching upon but sparing fixation) demonstrated a differential response to focal 
laser therapy (ETDRS 1985). The ETDRS presented data indicating that treatment of center-
involving CSME resulted in a 67% decrease in the rate of visual loss (defined as 15 or more 
letter at three years). However, the treatment of center-sparing CSME resulted in only an 
approximate 45% decrease in the rate of visual loss. The ETDRS was not designed to 
determine the most appropriate timing for focal laser therapy. However, based on its 
conclusions, immediate focal laser photocoagulation is recommended in both morphologies 
of CSME.  
The management of diabetic macular edema has expanded since publication of the ETDRS 
findings. At present, treatment options are quite broad, incorporating proven and new 
therapies (or combinations of them), each designed to target a central pathophysiologic 
mechanism of the disease. Three proven methods exist to decrease the long-term risk of 
vision loss from DME, namely (1) tight blood sugar control (proven in Diabetes Control and 
Complications Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS)); (2) 
blood pressure control (UKPDS); and (3) focal laser photocoagulation therapy (ETDRS) 
(ETDRS 1985; DCCT 1983; UKPDS 1998). 
Observation with encouragement of tight glycemic and blood pressure control is an option, 
particularly in subclinical macular edema (SCME). While spontaneous resolution of macular 
edema with excellent control of systemic risk factors is entirely possible, observation of 
patients deemed at high risk for clinical worsening is not advisable. In fact, the ETDRS did 
recommend focal laser therapy for macular edema outside 500 microns of fixation in the 
context of poor glycemic control (ETDRS 1985). 
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5.1 Focal laser photocoagulation therapy 
Since the findings of ETDRS, focal laser photocoagulation remains the standard of care for 
the treatment of diabetic macular edema. The effects of focal laser in controlling macular 
edema are relatively long-lasting, demonstrated at up to three years. However, as was 
reported by the ETDRS, only 17% of eyes with baseline vision of worse than 20/40 
experienced modest visual improvement, and a certain proportion of patients did not 
respond to focal laser therapy at all (ETDRS 1985). It is generally accepted that diffuse DME 
or cystoid macular edema in fixation precludes treatment by focal laser by virtue of its 
location. The more severe entities of DME have served as an impetus in the search for 
adjunctive or stand-alone pharmacotherapy in the treatment of diabetic macular edema. 
5.2 Steroid agents 
Steroid agents were an earlier first-line pharmacotherapy for diabetic macular edema. 
Triamcinolone acetonide and its newer, unpreserved formulation (for intravitreal injection) 
have been used as adjuncts of focal laser or stand-alone alternatives. The utility of 
peribulbar and intravitreal steroid injections has been established in the management of 
intraocular inflammation and cystoid macular edema secondary to non-infectious uveitis. 
(Kok, 2005); (Tanner, 1995). As such, attention was turned to employ this method as a 
possible treatment for DME. Initial efficacy studies conducted between 2001 and 2002 
demonstrated a short-term therapeutic effect of a randomly selected 4 mg dose of 
intravitreal triamcinolone injection in DME, and its use became widespread despite a lack of 
data from randomized, prospective clinical trials assessing efficacy or possible adverse 
effects (Jonas 2001; Martidis 2002).  
Peribulbar triamcinolone has likewise been employed as a treatment modality for diabetic 
macular edema. Peribulbar injection is commonly delivered at a dosage of 20 – 40 mg of 
triamcinolone acetonide (40mg/1ml ) solution to one of three potential peribulbar locations: 
(1) anterior subconjunctival or subtenons; (2) posterior subtenons; (3) retrobulbar. Its 
hypothesized mechanism of action in treating diabetic macular edema involves a 
combination of decreasing retinal vascular permeability by downregulation of VEGF 
expression and decreasing leukostasis in retinal capillaries (Kern 2007).  
A review of the literature reveals inconsistent reports of the efficacy of peribulbar steroid 
injection in treating DME. One retrospective study reported the efficacy of 40mg/1 ml 
posterior subtenons triamcinolone injection in eyes with DME and moderate vision loss 
(defined as a mean visual acuity of 20/80). Twenty-two percent of enrolled patients 
maintained a three or more line improvement in vision at 12 months (Bakri 2005). One study 
that compared posterior subtenons triamcinolone to placebo/sham injection in eyes with a 
mean visual acuity of 20/160 and fairly recalcitrant macular edema found no statistically 
significant improvement in visual acuity or decline in central retinal thickness (Entezari 
2005). Another study enrolled patients with only mild diabetic macular edema and a mean 
visual acuity of 20/25. This study employed three arms to compare stand-alone peribulbar 
(anterior and posterior subtenons) therapy with focal laser photocoagulation therapy and a 
combination injection-laser therapy. After 34 weeks of follow-up, there was no conclusive 
improvement in visual acuity or decrement in central macular thickness in any of the 
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treatment arms. However, a statistical trend indicated a decrease in the likelihood of re-
injection if the injection was followed in the short term by focal laser (Chew 2007). A 
retrospective uncontrolled study reported that intravitreal triamcinolone was superior to a 
posterior subtenons delivery of the drug (Ozdek 2006). 
In September 2008, the Diabetic Retinopathy Clinical Research Network published the two-
year results of a multi-center, large scale, randomized clinical trial directly comparing the 
efficacy of focal laser therapy and intravitreal triamcinolone injections (1mg and 4 mg 
dosages) with visual acuity and central retinal thickness as primary outcome variables 
(Figueroa 2008). The original study population met strict inclusion and exclusion criteria 
and had a wide range of visual acuity and DME severity. The findings of this study declared 
a short-term benefit of 4 mg triamcinolone over the other groups at four months, no clear 
benefit of any modality at 12 months, and a clear benefit of focal laser over either steroid 
dosage at two years in terms of improvement in mean visual acuity. Retinal thickness 
parameters generally paralleled the trends in visual acuity in this study. Adverse effects, 
including cataract formation and intraocular pressure increase, were monitored during this 
study. Intravitreal steroids demonstrated higher rates of cataract formation. Importantly, the 
reversal of efficacy of focal laser over intravitreal steroid over two years was not 
confounded by cataract formation (Figueroa 2008). The identical three-year follow-up data 
were reported by this group in 2009 (Beck RW 2009). Thus focal laser therapy was proven to 
have a lasting effect on vision with a much safer side effect profile when compared to 
varying dosages of intravitreal triamcinolone acetonide.  
5.3 Anti-Vascular Endothelial Growth Factor (VEGF) agents  
The newest therapy in diabetic macular edema comprises biologic agents engineered to 
target the root cause of retinal vascular permeability, namely VEGF expression. VEGF-A 
is a known regulator protein of angiogenesis, vascular permeability, and pro-
inflammatory activity (Murugeswari 2008; Roberts 1995). It binds VEGFR1 and VEGFR2 
receptors and is upregulated primarily in response to tissue ischemia, inflammation, pH 
changes, and hormone growth factors (Penn 2008). Ranibizumab and bevacizumab are 
sister molecules of humanized murine monoclonal antibodies with affinity for binding 
VEGF isoforms. Ranibizumab (or Lucentis) is a humanized anti-VEGF-A recombinant Fab 
fragment (molecular weight 48 kDa), which binds all isoforms of VEGF A. Bevacizumab 
(or Avastin) is a full-length humanized antibody to VEGF-A (molecular weight 149 kDa) 
that binds all VEGF isoforms. Similar to triamcinolone acetonide, the delivery of both 
drugs is by intravitreal injection. Ranibizumab (or Lucentis) gained attention after 
approval by the United States Food and Drug administration in the management of 
exudative age-related macular edema (ARMD) in 2006. Bevacizumab (or Avastin) was 
initially approved as adjunctive chemotherapy of metastatic colon cancer and has been 
widely used in an off-label fashion in the treatment of exudative ARMD. These drugs 
have likewise been applied to treat macular edema secondary to diabetic retinopathy and 
retinal vein occlusions. 
The efficacy of the anti-VEGF agents in diabetic macular edema has been the subject of 
several recent investigations. Arevalo and colleagues report efficacy data from the Pan-
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American Collaborative Retina study group (Arevalo 2007). This retrospective 
interventional multicenter study evaluated the retinal thickness and ETDRS acuity data of 
80 consecutive patients receiving intravitreal Avastin injections for center-involving diabetic 
macular edema in eyes not previously treated with focal laser. Eyes received at least one 
Avastin injection (either 1.25mg or 2.50mg) with smaller percentages of patients requiring a 
second or third injection over a six-month period (on average every 11 to 13 weeks). The 
group reported a favorable decline in OCT retinal thickness and visual acuities that were 
stable if not improved from baseline (Arevalo 2007). The 24-month extension of this study 
supported the six-month findings. Patients who received on average 5.8 injections of single 
or double dose Avastin demonstrated a partial resolution of macular edema and 
maintained, if not improved, upon baseline visual acuity (Arevalo 2009). To date, there has 
been no formal large-scale phase III randomized control trial for the efficacy of anti-VEGF 
agents in diabetic macular edema.  
Additional studies have emerged to compare the efficacy of anti-VEGF therapy to focal 
laser photocoagulation in DME. The Bevacizumab or Laser Therapy (or BOLT) study was 
a prospective, randomized phase II clinical trial and a first of its kind to compare anti-
VEGF therapy to focal laser therapy (Michaelidis 2010). The study randomized 80 eyes to 
receive either intravitreal bevacizumab injections (1.25mg/0.50ml) or macula laser 
therapy (MLT) group. Bevacizumab injections were given every six weeks for the first 
three months followed by as needed thereafter. Focal laser was offered initially and every 
four months as needed. Injected eyes received a minimum of three and maximum of nine 
injections, whereas the focal laser eyes received a minimum of one and maximum of four 
treatments in the 12-month study period. The primary outcome measure was ETDRS 
visual acuity. The study reported a statistically significant difference in mean ETDRS 
visual acuity in the bevacizumab group (61.3±10.4) as compared to the MLT group 
(50.0±16.6, P = 0.0006). Patients in the bevacizumab group were 5.1 times as likely to gain 
at least 10 ETDRS letters. Analogously, data on central retinal thickness showed a larger 
decrease from baseline in the bevacizumab group than the focal laser group. The BOLT 
study suggested that intravitreal bevacizumab therapy should be considered as a first 
choice in the management of center-involving DME. However, its use must be undertaken 
prudently in the setting of excellent visual acuity, as intravitreal injection is not without 
risk of complications.  
5.4 Surgical management 
Identification of vitreomacular traction (as in VMT syndrome) highlights the possible utility 
of pars plana vitrectomy in eliminating at least one factor that exacerbates diabetic macular 
edema. This was formally evaluated by the Diabetic Retinopathy Clinical Research network 
in a prospective cohort study (Haller 2010). This study was the first of its kind to 
systematically evaluate the effect of pars plana vitrectomy on visual acuity and retinal 
thickness outcomes in patients with diabetic macular edema who demonstrated 
vitreomacular traction on time-domain (Stratus) OCT. The study evaluated one eye from 87 
diabetic patients with moderate visual loss (defined in the study as VA ranging from 20/63 
– 20/400), a central retinal subfield thickness of >300 microns (by Stratus OCT), and 
evidence by OCT of vitreomacular traction (as assessed by the clinician). These eyes 
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underwent standard pars plana vitrectomy and were followed at 3, 6, and 12 months. Six-
month data from the study has been published. Care was taken to eliminate confounding 
factors with strict exclusion criteria. This study revealed that pars plana vitrectomy for eyes 
with DME and VMT quantitatively decreased the degree of macular edema. However, the 
visual acuity outcomes were less predictable in that study patients exhibited both an 
improvement (38%, 10 letters or more) or a decrement (22%, 10 letters or more). A major 
weakness of this study was the lack of a control group to demonstrate the natural course of 
eyes with vitreomacular traction (which the authors deemed unethical). Given the 
variability in operative outcomes of vitrectomy for vitreomacular traction in diabetic 
macular edema, this treatment modality requires further investigation.  
6. Conclusion 
With the increasing incidence of all types of diabetes mellitus in the United States and 
worldwide, diabetic macular edema will continue to represent a widespread cause of visual 
morbidity. A solid understanding of the basic pathophysiologic mechanisms of this disease 
is critical in the clinical evaluation, severity assessment, appropriate treatment selection, and 
effective patient counseling. Strict glycemic and blood pressure control are the most 
effective methods of treating DME, as they directly target the root cause of the problem: 
hyperglycemia, hypertension, microvascular damage and retinal vessel incompetence. Focal 
laser photocoagulation therapy is an advantageous, though time-limited, treatment that 
remains the standard of care for DME. More recent therapies have targeted the 
inflammatory pathways of this disease on a molecular level and have shown promising 
results. There is a role of surgical intervention when tractional membranes are believed to 
exacerbate macular edema. Further study is required to establish which of the available 
treatment modalities are superior. At present, successful treatment of diabetic macular 
edema requires thorough patient education, counseling, and compliance such that a 
mutually acceptable treatment protocol can be established and pursued.  
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